WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Mexico DF, Mexico
-
-
-
-
-
Lima, Peru
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
Tuscumbia, Alabama, United States
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
Searcy, Arkansas, United States
-
-
California
-
Concord, California, United States
-
Irvine, California, United States
-
La Jolla, California, United States
-
Los Angeles, California, United States
-
Los Gatos, California, United States
-
West Hills, California, United States
-
-
Florida
-
Coral Gables, Florida, United States
-
Miami, Florida, United States
-
New Port Richey, Florida, United States
-
Pembroke Pines, Florida, United States
-
West Palm Beach, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Louisiana
-
New Orleans, Louisiana, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Missouri
-
Kansas City, Missouri, United States
-
St. Louis, Missouri, United States
-
-
New York
-
Rochester, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
Hickory, North Carolina, United States
-
Statesville, North Carolina, United States
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
Cleveland, Ohio, United States
-
Marion, Ohio, United States
-
Perrysburg, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
Tulsa, Oklahoma, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Beaver, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
-
Tennessee
-
Bristol, Tennessee, United States
-
-
Texas
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
Midland, Texas, United States
-
San Antonio, Texas, United States
-
-
Virginia
-
Arlington, Virginia, United States
-
Richmond, Virginia, United States
-
-
Washington
-
Lakewood, Washington, United States
-
Renton, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years, inclusive
- Diagnosed with type 2 diabetes
- Stable dose of sulfonylurea alone or in combination with other anti-diabetic medications for 90 days
- Hemoglobin A1c value 7.5% to 9.5%, inclusive
- C peptide > 0.5 ng/mL
- Prescribed ADA diet
Exclusion Criteria:
- History of type 1 diabetes or ketoacidosis
- History of pancreatitis
- Uncontrolled hypertension
- Allergy or toxic response to colesevelam or any of its components
- Serum LDL-C < 60 mg/dL
- Serum TG > 500 mg/dL
- Body mass index (BMI) > 45 kg/m2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
To assess the additional lowering of HbA1c achieved by addition of colesevelam hydrochloride to current antidiabetic therapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
To assess the improvement in insulin sensitivity;
|
|
To assess the fasting plasma glucose and fructosamine lowering efficacy;
|
|
To assess glycemic control response rate;
|
|
To assess the effect on C reactive protein;
|
|
To assess lipids and lipoproteins;
|
|
To assess the safety and tolerability of colesevelam hydrochloride as add-on therapy
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WEL-303
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.